Integer (NYSE:ITGR) PT Raised to $130.00

Integer (NYSE:ITGR) had its price target upped by research analysts at Citigroup from $124.00 to $130.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical equipment provider’s stock. Citigroup’s target price suggests a potential upside of 0.99% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Bank of America boosted their price objective on shares of Integer from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. Benchmark reissued a “buy” rating and set a $130.00 price objective on shares of Integer in a report on Friday, August 2nd. Oppenheimer started coverage on shares of Integer in a report on Tuesday, July 16th. They set an “outperform” rating and a $135.00 price objective for the company. Finally, Truist Financial boosted their price objective on shares of Integer from $137.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $137.29.

Integer Stock Down 1.0 %

Integer stock traded down $1.28 during trading hours on Tuesday, hitting $128.72. The stock had a trading volume of 69,520 shares, compared to its average volume of 316,304. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.73. The stock has a market capitalization of $4.31 billion, a P/E ratio of 44.53, a price-to-earnings-growth ratio of 1.87 and a beta of 1.09. Integer has a 12-month low of $69.40 and a 12-month high of $131.87. The stock’s 50-day moving average price is $123.35 and its 200-day moving average price is $119.22.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, July 25th. The medical equipment provider reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.06. The business had revenue of $436.20 million during the quarter, compared to analysts’ expectations of $437.00 million. Integer had a net margin of 6.31% and a return on equity of 11.48%. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share. Equities research analysts anticipate that Integer will post 5.31 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jean M. Hobby sold 11,960 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the completion of the transaction, the director now owns 2,280 shares in the company, valued at $272,824.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Integer

A number of hedge funds have recently bought and sold shares of ITGR. Quest Partners LLC raised its stake in Integer by 3,688.9% during the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 332 shares in the last quarter. GAMMA Investing LLC raised its stake in Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 142 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Integer during the first quarter valued at $106,000. Innealta Capital LLC purchased a new stake in shares of Integer in the second quarter valued at $110,000. Finally, Hancock Whitney Corp purchased a new stake in shares of Integer in the first quarter valued at $203,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.